Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
4 Low-Beta Stocks to Buy to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
HAE vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
by Zacks Equity Research
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
by Zacks Equity Research
Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
Quest Diagnostics (DGX) Acquires Northern Light Laboratory
by Zacks Equity Research
Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.
NuVasive's (NUVA) Precice System Cleared for Pediatric Patients
by Zacks Equity Research
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
by Zacks Equity Research
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth
by Zacks Equity Research
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.
Bruker (BRKR) Receives 1.2 GHz NMR System Orders From the UK
by Zacks Equity Research
Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
by Zacks Equity Research
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Medtronic's (MDT) Affera Ablation System Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.
Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes
by Zacks Equity Research
Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.